CMV-reactive Vdelta1 gd T cells are equally cytotoxic to
CMV-specific ab T cells in HLA-A*02 healthy donors

a 2022

CMV-reactive Vdelta1 gd T cells are equally cytotoxic to CMV-specific ab T cells in HLA-A*02 healthy donors

TOLOCHOVA, Petra, Martin PISKÁČEK, Renata HÉŽOVÁ, Elleni MICHU, Ondřej SLABÝ et. al.

Basic information

Original name

CMV-reactive Vdelta1 gd T cells are equally cytotoxic to CMV-specific ab T cells in HLA-A*02 healthy donors

Authors

TOLOCHOVA, Petra, Martin PISKÁČEK (40 Austria, belonging to the institution), Renata HÉŽOVÁ (203 Czech Republic), Elleni MICHU (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Andrea KNIGHT (203 Czech Republic, belonging to the institution)

Edition

8th International Congenital CMV Conference & 18th International CMV Workshop, 28th March-1st April 2022 Cambridge, 2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30102 Immunology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/22:00129661

Organization unit

Faculty of Medicine

Keywords in English

CMV-reactive Vdelta1 gd T cells

Abstract

V originále

Cytomegalovirus (CMV) infection is responsible for significant morbidity and mortality in immunocompromised patients, namely haematopoietic cell transplant recipients (HCT) despite prophylaxis and pre-emptive treatment. Earlier, we demonstrated the role of Vdelta1 gamma-delta (gd) T cells in the reconstitution of CMV immunity post-transplant. Here, we analysed CMV+ healthy donors with five most commonly presented alleles including HLA-A*02 (n=23), HLA-A*01 (n=17), HLA-A*24 (n=10), HLA-B*07 (n=5) and HLA-B*35 (n=10) for frequencies and phenotypes of Vd1+ gd T cells and CMV-specific alpha-beta (ab) T cells in the same donors. Multicolour flow cytometry was used to directly compare Vd1 gd T cells with donor paired CMV-specific ab T cells that have been identified by CMV-specific MHC Pentamers (ProImmune Limited, UK) for HLA-A*0201 (NLV), HLA-A*0101 (YSE), HLA-A*2402 (VYA), HLA-B*0702 (TPR) and HLA-B*3501 (IPS) alleles. Second, we determined the cytotoxic reactivity of ab and gd T cells against CMV-infected MRC-5 fibroblasts in HLA-A*02 donors in 4h flow cytometric killing assays. Both, ab CMV-specific T cells and pair-matched freshly isolated or ex-vivo cultured Vd1 gd T cells were highly lytic to CMV-infected targets at 10:1 E:T ratio with no significant differences in specific lysis observed between the ab and gd T cells (p>0.05). Next, we compared the microRNA (miRNA) expression profiles for Vd1 gd T cells and ab T cells isolated from the same HLA-A*02 and HLA-A*01 donors. We identified 20 miRNAs differentially expressed (P<0.001) for HLA-A*02 and 10 miRNAs for HLA-A*01 allele (P<0.05) known to be associated with suppression of tumour cell proliferation, invasion and metastasis in addition to regulating inflammation in multiple cancers predicting patient prognosis and disease outcome. In summary, we provide further evidence for CMV reactive Vd1 gd T cells implicated in CMV chronic infection that could be used in adoptive transfer in HCT recipients regardless of HLA status.

Links

NV19-05-00410, research and development project

Name: Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme

Investor: Ministry of Health of the CR

Citovat

TOLOCHOVA, Petra, Martin PISKÁČEK, Renata HÉŽOVÁ, Elleni MICHU, Ondřej SLABÝ and Andrea KNIGHT. CMV-reactive Vdelta1 gd T cells are equally cytotoxic to CMV-specific ab T cells in HLA-A*02 healthy donors. In 8th International Congenital CMV Conference & 18th International CMV Workshop, 28th March-1st April 2022 Cambridge. 2022.

@proceedings{1830137,
   author = {Tolochova, Petra and Piskáček, Martin and Héžová, Renata and Michu, Elleni and Slabý, Ondřej and Knight, Andrea},
   booktitle = {8th International Congenital CMV Conference & 18th International CMV Workshop, 28th March-1st April 2022 Cambridge},
   keywords = {CMV-reactive Vdelta1 gd T cells},
   language = {eng},
   title = {CMV-reactive Vdelta1 gd T cells are equally cytotoxic to CMV-specific ab T cells in HLA-A*02 healthy donors},
   year = {2022}
}

TY  - CONF
ID  - 1830137
AU  - Tolochova, Petra - Piskáček, Martin - Héžová, Renata - Michu, Elleni - Slabý, Ondřej - Knight, Andrea
PY  - 2022
TI  - CMV-reactive Vdelta1 gd T cells are equally cytotoxic to CMV-specific ab T cells in HLA-A*02 healthy donors
KW  - CMV-reactive Vdelta1 gd T cells
N2  - Cytomegalovirus (CMV) infection is responsible for significant morbidity and mortality in immunocompromised patients, namely haematopoietic cell transplant recipients (HCT) despite prophylaxis and pre-emptive treatment. Earlier, we demonstrated the role of Vdelta1 gamma-delta (gd) T cells in the reconstitution of CMV immunity post-transplant. Here, we analysed CMV+ healthy donors with five most commonly presented alleles including HLA-A*02 (n=23), HLA-A*01 (n=17), HLA-A*24 (n=10), HLA-B*07 (n=5) and HLA-B*35 (n=10) for frequencies and phenotypes of Vd1+ gd T cells and CMV-specific alpha-beta (ab) T cells in the same donors. Multicolour flow cytometry was used to directly compare Vd1 gd T cells with donor paired CMV-specific ab T cells that have been identified by CMV-specific MHC Pentamers (ProImmune Limited, UK) for HLA-A*0201 (NLV), HLA-A*0101 (YSE), HLA-A*2402 (VYA), HLA-B*0702 (TPR) and HLA-B*3501 (IPS) alleles. Second, we determined the cytotoxic reactivity of ab and gd T cells against CMV-infected MRC-5 fibroblasts in HLA-A*02 donors in 4h flow cytometric killing assays. Both, ab CMV-specific T cells and pair-matched freshly isolated or ex-vivo cultured Vd1 gd T cells were highly lytic to CMV-infected targets at 10:1 E:T ratio with no significant differences in specific lysis observed between the ab and gd T cells (p>0.05). Next, we compared the microRNA (miRNA) expression profiles for Vd1 gd T cells and ab T cells isolated from the same HLA-A*02 and HLA-A*01 donors. We identified 20 miRNAs differentially expressed (P<0.001) for HLA-A*02 and 10 miRNAs for HLA-A*01 allele (P<0.05) known to be associated with suppression of tumour cell proliferation, invasion and metastasis in addition to regulating inflammation in multiple cancers predicting patient prognosis and disease outcome. In summary, we provide further evidence for CMV reactive Vd1 gd T cells implicated in CMV chronic infection that could be used in adoptive transfer in HCT recipients regardless of HLA status.
ER  -

TOLOCHOVA, Petra, Martin PISKÁČEK, Renata HÉŽOVÁ, Elleni MICHU, Ondřej SLABÝ and Andrea KNIGHT. CMV-reactive Vdelta1 gd T cells are equally cytotoxic to CMV-specific ab T cells in HLA-A*02 healthy donors. In \textit{8th International Congenital CMV Conference \&{} 18th International CMV Workshop, 28th March-1st April 2022 Cambridge}. 2022.

Detailed Information on Publication Record